Data from: Ten-year survival trends of neovascular age-related macular degeneration at first presentation
Cristina Arpa, Hagar Khalid, Shruti Chandra, Siegfried Wagner, Katrin Fasler, Livia Faes, Pakinee Pooprasert, Reena Chopra, Gabriella Moraes, Konstantinos Balaskas, Pearse Keane, Sobha Sivaprasad & Dun Jack Fu
Background: To describe 10-year trends in visual outcomes, anatomical outcomes, and treatment burden of patients receiving anti-vascular endothelial growth factor (VEGF) therapy for neovascular age-related macular degeneration (nAMD). Methods: Retrospective cohort study of treatment-naïve, first-affected eyes with nAMD started on ranibizumab before January 1, 2009. The primary outcome was time to best-corrected visual acuity (BCVA) falling ≤ 35 Early Treatment Diabetic Retinopathy Study (ETDRS) letters after initiating anti-VEGF therapy. Secondary outcomes included time to BCVA...